16Jun, 2020
Savara’s Key Activities in the Coming Quarters
0 CommentsDear Shareholders, There has been a flurry of activity recently and I wanted to take this opportunity to reconnect with... Read More
26Feb, 2020
Introduction to Savara’s Chief Medical Officer
0 CommentsDear Shareholders, After wrapping up our three-part series on autoimmune pulmonary alveolar proteinosis (aPAP) that provided perspectives on the disease... Read More
17Dec, 2019
Interview with an aPAP Advocate
0 CommentsDear Shareholders, Our last two blog entries focused on the rare lung disease autoimmune pulmonary alveolar proteinosis (aPAP). Treatment of... Read More
11Sep, 2019
Interview with a Woman Living with aPAP
0 CommentsDear Shareholders, The last entry we posted was written by guest blogger, Dr. Bruce Trapnell. He provided a physician’s perspective... Read More
08May, 2019
Investigating GM-CSF in aPAP: A Logical Replacement of a Dysfunctional Protein
0 CommentsInvestigating GM-CSF in aPAP: A Logical Replacement of a Dysfunctional Protein ―Bruce Trapnell, M.D. Autoimmune pulmonary alveolar proteinosis (aPAP) is... Read More
28Feb, 2019
Dear Stockholders
0 CommentsDear Shareholders, Today is February 28, Rare Disease Day, which is focused on raising awareness about the prevalence and impact... Read More
13Dec, 2018
Dear Stockholders
0 CommentsDear Shareholders, With 2018 coming to a close, it’s a good time to look back and reflect on Savara’s progress... Read More
17Jul, 2018
Dear Stockholders
0 CommentsDear Shareholders, As we head into the summer, I’m excited to highlight some of our key recent accomplishments as well... Read More
28Feb, 2018
Dear Stockholders
0 CommentsDear Shareholders, Today marks the 10th anniversary of Rare Disease Day, a day dedicated to raising awareness about the dire... Read More
29Jan, 2018
Dear Stockholders
0 CommentsDear Shareholders, For Savara, 2017 was a transformative year with notable corporate achievements on our journey of building Savara into... Read More
09Nov, 2017
Dear Stockholders
0 CommentsDear Stockholders, It has been an incredibly productive third quarter for Savara on several fronts. We have continued to execute... Read More
06Sep, 2017
Dear Stockholders
0 CommentsDear Stockholders, As you may have seen, yesterday we announced that we will be presenting at the Rodman & Renshaw... Read More
25Jul, 2017
Dear Stockholders
0 CommentsDear Stockholders, First, we would like to thank you for your continued interest and support in Savara. We see Savara... Read More
19Mar, 2017
Mast Therapeutics sets date for special meeting of stockholders to vote on proposed merger with Savara
0 CommentsSpecial Meeting To Be Held on April 21, 2017 SAN DIEGO, CA and AUSTIN, TX – March 16, 2017 –... Read More
07Jan, 2017
Mast Therapeutics and Savara sign merger agreement
0 CommentsProposed Merger Creates Specialty Pharmaceutical Company with Three Clinical-Stage Inhaled Product Candidates for Serious and Life-Threatening Diseases Conference Call Scheduled... Read More
02Nov, 2016
Savara Pharmaceuticals appoints David L. Lowrance as CFO
0 CommentsAustin, Texas – November 2, 2016 – Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today... Read More
18Jul, 2016
Savara Completes Acquisition of Serendex
0 CommentsStrengthens pipeline serving patients with rare respiratory diseases Austin, Texas – July 18, 2016 – Savara Pharmaceuticals, an emerging specialty... Read More
21Jun, 2016
Savara Pharmaceuticals Acquires Serendex Pharmaceuticals
0 CommentsAdds two orphan respiratory drugs to its growing pipeline Austin, Texas – June 21, 2016 Savara Pharmaceuticals, an emerging specialty... Read More
09Jun, 2016
Savara Pharmaceuticals To Present At The Jefferies 2016 Healthcare Conference
0 CommentsNew York City – June 9, 2016 Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today... Read More
25May, 2016
First patient dosed in Savara’s pivotal trial for PAP
0 CommentsSavara’s phase II/III clinical trial of lead drug candidate Molgradex® for patients with pulmonary alveolar proteinosis (PAP) has included its... Read More
12May, 2016
Savara signs license agreement with Japanese partner
0 CommentsSavara signs license agreement with Japanese Nobelpharma Co. Ltd for future commercialisation of Molgradex® in Japan. With reference to earlier... Read More
01Mar, 2016
Savara Pharmaceuticals Completes $20 Million Round of Financing
0 CommentsPreparation underway for Phase 3 trial of AeroVanc for MRSA lung infection in people with cystic fibrosis Austin, TX –... Read More
23Feb, 2015
Savara Pharmaceuticals’ AeroVanc Meets Primary Endpoint of MRSA Reduction in Phase 2 Trial in People with Cystic Fibrosis
0 CommentsTrial also demonstrates strong trends in secondary clinical endpoints Austin, TX – February 23, 2015 Savara Pharmaceuticals announced today positive... Read More